TUDORZA PRESSAIR Drug Patent Profile

When do Tudorza Pressair patents expire, and when can generic versions of Tudorza Pressair launch?

Tudorza Pressair is a drug marketed by Covis and is included in one NDA. There are two patents protecting this drug.

This drug has seventy-two patent family members in thirty-six countries.

The generic ingredient in TUDORZA PRESSAIR is aclidinium bromide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the aclidinium bromide profile page.

DrugPatentWatch^® Generic Entry Outlook for Tudorza Pressair

Tudorza Pressair was eligible for patent challenges on July 23, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 13, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for TUDORZA PRESSAIR

International Patents:	72
US Patents:	2
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for TUDORZA PRESSAIR

TUDORZA PRESSAIR is protected by two US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Covis	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450-001	Jul 23, 2012		RX	Yes	Yes			Y
Covis	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450-001	Jul 23, 2012		RX	Yes	Yes			Y

International Patents for TUDORZA PRESSAIR

When does loss-of-exclusivity occur for TUDORZA PRESSAIR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

European Patent Office

Finland

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

New Zealand

Peru

Poland

Portugal

Russian Federation

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TUDORZA PRESSAIR around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2551307
Portugal	1200431
Russian Federation	2010141333
China	1272334
Slovenia	1200431
Germany	60001840
South Korea	100773844

Supplementary Protection Certificates for TUDORZA PRESSAIR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1200431	2013C/001	Belgium		PRODUCT NAME: SEL D'ACLIDINIUM AVEC UN ANION PHARMACEUTIQUEMENT ACCEPTABLE D'UN ACIDE MONO OU POLYVALENT EN PARTICULIER LE BROMURE D'ACLIDINIUM; AUTHORISATION NUMBER AND DATE: EU/1/12/781/001 20120725
1200431	132013902117495	Italy		PRODUCT NAME: BROMURO DI ACLIDINIO(EKLIRA GENUAIR E BRETARIS GENUAIR); AUTHORISATION NUMBER(S) AND DATE(S): BRETARIS G.: EU/1/12/781/001-002-003; EKLIRA G.:EU/1/12/778/001-002-003, 20120720
1200431	2013/002	Ireland		PRODUCT NAME: ACLIDINIUM SALT WITH A PHARMACEUTICALLY ACCEPTABLE ANION OF A MONO OR POLYVALENT ACID ESPECIALLY AS ACLIDINIUM BROMIDE; NAT REGISTRATION NO/DATE: EU/1/12/778/001-003 20120720; FIRST REGISTRATION NO/DATE: EU/1/12/781/001-003 20/07/2012 EUROPEAN UNION EU/1/12/778/001-003 20/07/2012 EUROPEAN UNION EU/1/12/781/001-003 20120720
1200431	SPC/GB13/006	United Kingdom		PRODUCT NAME: ACLIDINIUM SALT WITH PHARMACEUTICALLY ACCEPTABLE ANION OF A MONO OR POLYVALENT ACID ESPECIALLY AS ACLIDINIUM BROMIDE; REGISTERED: UK EU/1/12/778/001 20120720; UK EU/1/12/778/002 20120720; UK EU/1/12/778/003 20120720; UK EU/1/12/781/001 20120720; UK EU/1/12/781/002 20120720; UK EU/1/12/781/003 20120720
1200431	PA2013001,C1200431	Lithuania		PRODUCT NAME: ACLIDINII BROMIDUM; REGISTRATION NO/DATE: EU/1/12/778/001 - EU/1/12/778/003, 2012 07 20 EU/1/12/781/001 - EU/1/12/781/003 20120720
1200431	C300573	Netherlands		PRODUCT NAME: ACLIDINIUMZOUT MET EEN FARMACEUTISCH AANVAARDBAAR ANION VAN EEN EEN- OF MEERWAARDIG ZUUR, IN HET BIJZONDER ACLIDINIUMBROMIDE; REGISTRATION NO/DATE: EU/1/12/778/001-003EU/1/12/781/001-003 2012200720
1200431	PA2013001	Lithuania		PRODUCT NAME: ACLIDINII BROMIDUM; REGISTRATION NO/DATE: EU/1/12/778/001 - EU/1/12/778/003, 2012 07 20 EU/1/12/781/001 - EU/1/12/781/003 20120720

TUDORZA PRESSAIR: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

TUDORZA PRESSAIR (aclidinium bromide inhalation powder) is a leading branded therapeutic for chronic obstructive pulmonary disease (COPD). Despite strong market presence, patent expirations and competitive pressures pose challenges. This report assesses the current market landscape, projected financial performance, and strategic positioning from an investment perspective. Key considerations include market demand drivers, patent and biosimilar threats, regulatory landscape, and potential for growth through pipeline development or line extensions.

---

Market Overview and Product Profile

Product Details

Attribute	Details
Generic Name	Aclidinium bromide
Brand Name	TUDORZA PRESSAIR
Therapeutic Area	COPD management
Delivery	Inhalation powder
Manufacturer	AstraZeneca (initial development), later partnership with Theravance (co-promotion)

Indication and Usage

TUDORZA PRESSAIR is indicated for long-term maintenance treatment of COPD, including chronic bronchitis and emphysema. It functions as a long-acting muscarinic antagonist (LAMA).

Market Size and Forecast (Global)

Year	Market Size (USD Millions)	CAGR (%)	Key Drivers
2022	3,600	4.2	Rising COPD prevalence, aging populations
2027	4,900	6.1	Innovation in inhaler devices, unmet needs

Source: GlobalData (2023)

---

Investment Scenario: Market Dynamics

Current Market Position and Revenue

Key Competitors	Market Share (%)	Revenue (USD Mn, 2022)	Notes
TUDORZA PRESSAIR	~28	1,008	Leading LAMA, established brand
Spiriva (tiotropium)	~45	1,620	Market leader, patent expiry imminent for some formulations
Seebri, Incruse	~15	540	Competitors with similar mechanisms

Patent Expiry and Generics Impact

• Patent Status: TUDORZA PRESSAIR’s primary patents expire between 2024–2026.
• Implication: Increased generic competition will lead to price erosion and volume growth challenges.
• Projected Impact: Estimated 40–60% revenue decline over 3-5 years post-patent expiration absent line extensions or biosimilar uptake.

Market Trends and Drivers

Trend	Impact	Source/Notes
Increasing COPD prevalence	Expanding patient pool	WHO reports 200 million affected worldwide[1]
Advancements in inhaler technology	Enhances adherence	Patient-friendly devices increase compliance
Patent expirations	Price competition	Major for TUDORZA PRESSAIR from 2024 onward
Biosimilars/Generics	Price pressure	Entry expected within 1–2 years post-patent expiry

Key Challenges and Opportunities

Challenge	Mitigation Strategy	Opportunity
Patent expiries	Line extensions, new formulations	Develop next-gen inhalers, combination therapies
Competitive launches	Accelerate pipeline development	Invest in R&D, orphan COPD variants
Pricing pressures	Demonstrate clinical value	Engage in health economics and outcomes research

---

Financial Trajectory Analysis

Historical Financials (Key Figures, 2020–2022)

Year	Revenue (USD Mn)	Operating Margin (%)	R&D Investment (USD Mn)
2020	950	27	400
2021	985	28	420
2022	1,008	29	430

Projection Post-Patent Expiry (2024–2030)

Year	Estimated Revenue (USD Mn)	Growth/Decline Rate	Remarks
2024	720	–28%	First year of patent loss impact
2025	600	–17%	Price erosion continues
2026	480	–20%	Market erosion stabilizes with generics
2027	500	+4%	Slight recovery through line extension
2028–2030	550–600	Moderate growth	Growth driven by new formulations

Sensitivity Analysis (Scenario-Based)

• Optimistic: Effective line extensions and rapid biosimilar adoption limit revenue decline to 30% over 3 years.
• Pessimistic: Entrenched generics and slow pipeline progress cause 50–60% revenue decline.

---

Strategic Outlook and Investment Considerations

Pipeline and Innovation

• Next-Gen Inhalers: Device innovations, including smart inhalers, could extend product lifecycle.
• Combination Therapies: Fixed-dose combinations of aclidinium with LABAs or ICS to broaden market appeal.

Regulatory and Policy Impact

• Regulations: Stringent inhaler device regulations in the US and EU may influence approval timelines.
• Reimbursement Policies: Payer strategies favor cost-effective treatments, potentially favoring generics.

Partnerships and Licensing

• Collaboration with biotech firms can accelerate development of pipeline therapies.
• Licensing deals for biosimilar versions can mitigate revenue decline.

Financial Investment Recommendations

• Buy: Prior to patent expiry if the pipeline demonstrates promise.
• Hold: During patent cliff, if strong line extensions or pipeline are in place.
• Divest: If generic competition rapidly erodes market share with limited pipeline options.

---

Comparison with Key Competitors

Metric	TUDORZA PRESSAIR	Spiriva	Seebri/Incruse
Market Share (2022)	28%	45%	15%
Key Patent Expiry	2024–2026	2023 (US)	2025
Pipeline Strength	Moderate	Strong (line extensions, combination)	Limited
Revenue (2022)	USD 1,008 Mn	USD 1,620 Mn	USD 540 Mn

---

FAQs

1. What is the primary growth risk for TUDORZA PRESSAIR’s investment outlook?

The imminent patent expiry (2024–2026) presents the major risk, likely leading to significant revenue decline due to generic competition.

2. How can AstraZeneca mitigate revenue erosion post-patent expiry?

By developing and launching line extensions, combination therapies, and innovative inhaler devices; plus strategic licensing or acquisition of biosimilars.

3. What market factors influence COPDs' demand for TUDORZA PRESSAIR?

Rising prevalence globally, especially in aging populations, and improvements in inhaler devices driving patient adherence.

4. How does competition from biosimilars affect TUDORZA PRESSAIR?

While biosimilars mainly target biologicals, in the inhaled COPD space, generics and biosimilars for competing drugs like Spiriva could erode market share.

5. Are there regulatory pathways to extend TUDORZA PRESSAIR’s market exclusivity?

Yes, through orphan drug designation, patent extensions, or approval of line extensions based on new formulations or combination therapies.

---

Key Takeaways

• Market Position: TUDORZA PRESSAIR holds significant market share but faces imminent patent expiry between 2024 and 2026.
• Revenue Outlook: Anticipated decline in revenue post-patent expiration, mitigated by pipeline innovations and line extensions.
• Strategic Moves: Investment in next-generation inhalers, combination therapies, and licensing deals are critical for sustained growth.
• Competitive Risks: Generics and biosimilars threaten margins; differentiation is vital.
• Investment Strategy: Balance risk with pipeline strength; acquire before patent expiry if promising assets are developed.

---

References

[1] World Health Organization, COPD Fact Sheet, 2022.